Connect Sign In
ARUP’s International Organization for Standardization (ISO) 15189 accreditation assessment has successfully concluded, and results confirm the consistently high quality of ARUP’s operations.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.
ARUP has launched a new, in-house test to detect the DNA of orthopoxviruses, including monkeypox.
Jonathan Genzen, MD, PhD, has been named chief medical officer and Adam Barker, PhD, has been named chief operations officer as part of a realignment of executive responsibilities.
ARUP Laboratories’ commitment to creating a supportive and satisfying work environment for employees has earned it a place on Forbes magazine’s list of America’s Best Employers for Diversity.
ARUP Laboratories has renamed its expert team of healthcare consultants as ARUP Healthcare Advisory Services. The new name better reflects the broad service offerings the team can provide.
ARUP’s commitment to creating a satisfying work environment for employees has earned it a spot on Forbes’ list of America’s Best Midsize Employers for 2022.
For the fourth consecutive year, Utah Business magazine has honored ARUP Laboratories with its Best Companies to Work For award. ARUP is one of 65 companies to earn the award.
PacBio and ARUP Laboratories announced they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.
